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Introduction
Hypertension is currently considered a major public health 
problem because of its importance as a cardiovascular risk factor. 
Worldwide, high blood pressure is estimated to cause 7.5 million 
deaths, about 12.8% of the total of all annual deaths [1]. Blood pressure 
levels have been shown to be positively and progressively related to the 
risk for stroke and coronary heart disease [2]. In addition to coronary 
heart diseases and stroke, complications of high blood pressure include 
heart failure, peripheral vascular disease, renal impairment, retinal 
haemorrhage and visual impairment [3].
The 33.3% of adult population in Spain suffer from hypertension 
[4]. Moreover, 1 out of every 4 deaths and 1 out of every 2.5 deaths 
caused by cardiovascular disease is related to high blood pressure [5].
A great number of national and international guidelines for 
hypertension treatment have been published. The JNC 7 guideline 
recommended diuretics as first-line treatment in hypertension [6].
Therefore the current Guidelines advise that diuretics (including 
thiazides, chlorthalidone and indapamide), beta-blockers, calcium 
antagonists, Angiotensin-Converting Enzyme (ACE) inhibitors and 
angiotensin receptor blockers are all suitable for the initiation and 
maintenance of antihypertensive treatment, either as monotherapy or 
in some combinations [7].
The European guideline, on the other hand, suggests that unless a 
special indication exists, any of the five antihypertensive classes can be 
used as first-line treatment [8]. Although the number of prescriptions 
for Diuretics (Ds) and Β-Blockers (BBs) is increasing, and for Calcium-
Channel Blockers (CCBs) is decreasing, in most countries the most 
frequently antihypertensive classes prescribed are still Angiotensin-
Converting Enzyme Inhibitors (ACEIs) or CCBs [9-15]. However, 
there is a considerable variation in the antihypertensive drug classes 
used in different countries [9-20].
The present study aimed to analyze the overall use and changes in 
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Abstract
Objective: This study aimed to describe the use of antihypertensive in Extremadura (Spain) from 1990 to 2012 
and its economic impact.
Method: Information on antihypertensive drug (ATC C02, C03, C07, C08, C09) utilization was obtained from the 
community pharmacy sales figures reimbursed by the Health System of Extremadura (Spain). Data were expressed 
in Defined Daily Dose (DDD) and DDD per 1000 inhabitants per day (DHD). 
Results: Antihypertensive consumption in Extremadura increased from 67.1 DHD in 1990 to 315.2 in 2012 (an 
increase of 3.7 times). Agents acting on the Renin-Angiotensin System (C09) are responsible for 75% of the total 
increase. Since 2007 the use of Angiotensin II antagonist increased over ACE inhibitors.
Conclusions: The consumption of antihypertensive drugs in Extremadura increased remarkably in the last 23 
years. In the last years the use of angiotensin II antagonist drugs is having a significant economic impact.
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the prescribing pattern of antihypertensive drugs by Family Medicine 
physicians in the Spanish region of Extremadura from 1990 to 2012, its 
compliance with guidelines, and its economic impact. 
Method
In order to study the use of antihypertensive drugs in Extremadura, 
annual data from 1 January 1990 to 31 December 2012 about the 
prescribing of antihypertensive drugs were collected from the 
community pharmacy sales figures reimbursed by the Spanish 
Extremadura Health System (SES), which covers almost 100% of the 
Extremadura population (1.100.000 inhabitants). 
All the antihypertensive drugs marketed in Spain and listed in the 
Anatomic Therapeutic Chemical (ATC) classification system were 
studied. The ATC studied groups studied are the followings: C02 
[Antihypertensives]; C03 [Diuretics]; C07 [Beta blocking agents]; 
C08 [Calcium channel blockers); C09 [Renin angiotensin system], 
including: C09A (Angiotensin-converting enzyme inhibitors (ACE 
inhibitors), C09B (ACE inhibitors, combinations), C09C (Angiotensin 
II antagonists), C09D (Angiotensin II antagonists, combinations).
Drug consumption figures were expressed as the number of 
Defined Daily Doses (DDD) per 1000 inhabitants per Day of Treatment 
(DHD), using the DDD values proposed by WHO [21].
Total costs were estimated by multiplying the number of sold 
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packages of each product by the price of each one. Cost per day was 
calculated by dividing the total cost by the total DDD consumed for the 
active ingredient or subgroup considered.
Study limitations: firstly, data were collected by auditing drug sales 
in all the pharmacies of Extremadura, which allowed us to estimate 
the prescription of antihypertensive drugs but not their real use; [22] 
second, the DDD methodology allows the possibility of analyzing 
trends of consumption over the years, but does not allow individual 
level analyses regarding the real DDD received by a patient daily.
Results
Antihypertensive consumption in Extremadura increased fivefold 
between 1990 and 2012 (Figure 1). It is estimated that in 1990 there 
were 73,781 people in treatment with an antihypertensive drug, 
increasing to 346,726 people in 2012.
Subgroup C09 (agents acting on the renin-angiotensin system) is 
responsible for 75% of the total increase (Figure 1).
Since 2007 the use of ARBs (C09C+C09D) increased over ACE 
inhibitors (C09A+C09B) (Figure 2).
The ranking of the most frequently prescribed renine-angyotensine 
drugs (C09) in the study period is shown in Table 1.
Total spending on antihypertensives (C02, C03, C07, C08 and C09) 
in 2012 was 42.5 million euros, of which 75.9% corresponds to the drug 
spending of the renin-angiotensin system (C09). Within this group, 
during the 2003-2012 spending on ACE inhibitors (C09A+C09B) 
decreased from 9.8 to 4.5 million euros, while in ARBs (C09C+C09D) 
increased from 22.1 to 27.0 million euros.
Discussion
There was an increase in the use of antihypertensive drugs in the 
study period, the same result was observed in similar studies performed 
in Spain [23-27]. This increase could be due to an increase in the 
number of people on antihypertensive treatment. It should be noted 
that antihypertensive drugs, except the C02 group, are not only used in 
hypertension, but also for treatment of other diseases such as diabetes, 
nephropathy, ischemic heart disease, peripheral arterial disease or 
stroke. Furthermore, the criteria for blood pressure control throughout 
the study period became more restrictive, considering as normal blood 
pressure values ever lower [6].Therefore, it is increasingly common 
to find patients taking more than one drug, and also patients that at 
the beginning of the study period would be considered normotensive, 
at period end would not be [6]. Other possible causes for the increase 
in the prescription of antihypertensives may be the aging population, 
changes in lifestyle, a better knowledge of the condition by the 
population, the implementation of Health Programmes at Primary 
Care. Furthermore must be taking into account the important role 
that have  the implementation on recent years of the ambulatory 
blood pressure monitoring and home blood pressure monitoring, 
these measures have facilitated the diagnosis and the management of 
hypertension, and have strengthened its prognostic value.
Study data shows that the total use of antihypertensives in 
Extremadura is higher than in other studies performed in Spain 
[25-27]. Extremadura is among the regions with higher rates of 
cardiovascular morbidity and mortality [28]and a high incidence of 
diabetic nephropathy and microalbuminuria [29,30] diseases that 
are related with the level of control of cardiovascular risk factors, 
particularly with high blood pressure. However, control of blood 
pressure in Extremadura is similar to the rest of Spain, 36.7% [31,32].
This rising use of antihypertensive over the past 20 years is not 
exclusive to Spain, also occurred in other European countries [33,34].
The increase in total use of antihypertensive drugs is mainly due 
to increased consumption of C09 group. The dramatic increase could 
be due to greater efficiency and tolerability of this group, although up 
today, clinical trials have failed to demonstrate greater efficacy and 
lower mortality of this group respect to others. Furthermore, it must be 
taken into account the possible influence of pharmaceutical companies. 
The C09 group is the most widely group used also in Europe, as it is 
shown in different European studies [33,34,38-40]. Within this group, 
the ACE inhibitors were the antihypertensive drugs most commonly 
used until 2007, at that moment they started to be replaced by ARBs. 











































































Figure 1: Antihypertensive drugs consumption in Extremadura, Spain (1990-
2012).(C02 Antihypertensives; C03 Diuretics; C07 Beta-blockers; C08 Calcium 



































































   
 . C09A+C09B
C09C+C09D
Figure 2: Angiotensin II antagonist (ARBs) and ACE inhibitors consumption in 
Extremadura, Spain (1990-2012).
1990 2000 2012
Drug % Drug % Drug %
Captopril 49.6 Enalapril 31.3 Enalapril 18.3
Enalapril 47.9 Candesartan 11.5 Candesartan 14.1
Captopril+diuretics 2.4 Ramipril 7.0 Ramipril 12.2
Valsartan 6.6 Valsartan 8.2
Olmesartan 5.3 Valsartan+diuretics 4.8
Table 1: Active ingredients most frequently prescribed in selected years, 
expressed in percentage of the total of the renin-angiotensin system drugs (C09).
Combinations are fixed.
Citation: Cáceres MC, Moyano P, Fariñas H, Cobaleda J, Pijierro A, Darado P,LLerena A  (2015) Trends in Antihypertensive Drug Use in Spanish 
Primary Health Care (1990-2012). Adv Pharmacoepidemiol Drug Saf 3: 172. doi:10.4172/2167-1052.1000172
Page 3 of 4
Volume 4 • Issue 1 • 1000172Adv Pharmacoepidemiol Drug SafISSN: 2167-1052 APDS, an open access journal 
since 2005 [27]. However Spanish data released shows that until 2006 
the ACE inhibitors were the antihypertensive most prescribed [24].
Captopril was the active ingredient most widely used in 1990; 
from 1991 to the end of the study period, enalapril remained as the 
most active ingredient prescribed, even after the marketing of ACE 
inhibitor. This trend is also observed in other studies published [25,26]. 
Considering the causes of high consumption of enalapril, it should be 
noted that enalapril has a good tolerability and a long half-life which 
allows an adequate blood pressure control with a single daily dose; it 
is also worth noting that as its action mechanism was better known, 
enalapril began to be used in the treatment of other diseases such as 
heart failure in normotensive patients and the prevention of diabetic 
nephropathy in diabetic patients.
From the point of view of therapeutic recommendations, 
therapeutic guidelines agree on Ds as first line treatment followed 
by BBS. Since the commercialization of ACE inhibitors and CCBs, 
they became part of the first-line treatment. Since 1997, the JNC VI, 
recommended by the first time ARBs only when the ACE inhibitor is 
not tolerated, but in 2003, both the JNC VII and the ESH-ESC 1, added 
ARBs as first-line treatment [6-8,35-37]. 
Despite all the measures that were taken in recent years to reduce 
drug spending, the significant increase in the use of antihypertensive 
drugs in the study period generated a major economic impact on the 
healthcare system, being due largely to the high cost of ARBs. This fact 
has been observed in other studies [24,27,33,40].
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